RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) vs Tilray Brands Inc — how do they compare? RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $38.01 (market cap $63.57B), while Tilray Brands Inc trades at $3.11 (market cap $481.79M). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is far larger — about 131.9× Tilray Brands Inc's market cap, and RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) pays a 2.49% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| RELX | TLRY | |
|---|---|---|
Market Cap | $63.57B | $481.79M |
Volume | 1,602,093 | 4,056,443 |
Sector | Industrials | Health |
52-Week High | $46.80 | $16.80 |
52-Week Low | $27.73 | $3.14 |
Enterprise Value | $75.05B | $635.71M |
Dividend Yield | 2.49% | — |
Typical Hold Time | — | 31 Days |
Signals from Pluang's Aura AI — not financial advice
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Tilray Brands (TLRY) trades at $3.27, down 2.68% on the day and near 52-week lows, with bearish technical signals dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings misses and negative cash flow from operations highlight ongoing profitability challenges despite analyst consensus pointing to significant upside potential.
TLRY presents a high-risk opportunity with substantial analyst price target divergence. While valuation metrics appear attractive (P/S 0.4x, P/B 0.3x), persistent losses and cash burn require careful monitoring. The stock's fate hinges on cannabis reform progress and the company's ability to achieve sustainable profitability amid competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →